

List of insider information under Art. 7 of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 regarding market abuse (Regulation on market abuse) on the circumstances that occurred in the fourth quarter of 2022

4 January 2022

“Sopharma” AD (the “Company”) announces that it was notified by “Telso” AD related to Vesela Stoeva, that “Telso” AD executed the following transactions related to shares in the Company:

Date and time of the transaction	Operation	Number of shares	Unit price (BGN)
30.12.2021	Buy	5 000	4,60
30.12.2021	Buy	4 000	4,58
30.12.2021	Buy	200	4,56
30.12.2021	Buy	438	4,56
30.12.2021	Buy	1 200	4,56
30.12.2021	Buy	3 162	4,56
30.12.2021	Buy	5 000	4,52
30.12.2021	Buy	20 000	4,48

6 January 2022

Conclusion of transactions from the scope of art. 114, para. 2 of the LPOS

Sofia, Bulgaria, January 6, 2022 – According to the requirements of Art. 100t of LPOS and in connection with Art. 114, para. 9 of the Law on Public Offering of Securities, “Sopharma” AD (SFA: BSE-Sofia, SPH: Warsaw Stock Exchange) announces that today, according to a decision of the Board of Directors dated December 21, 2021, the company concluded the following transactions falling within the scope of Art. 114, para. 2 of the LPOS:

1. “Sopharma” AD as a BUYER concluded a Contract for purchase and sale of 13 (thirteen) motor vehicles, owned by “Telecomplex” AD, UIC 831643753.

A) Participation of interested parties:

Ognian Donev is an interested person under Art. 114, para. 7, item 2 and item 3 of the LPOS, as on the one hand he is an Chairman of the Board of Directors and represents the public company “Sopharma” AD, and on the other hand, directly owns over 25% of the capital of “Telecomplex” AD and is a member of the Supervisory Board of the company - counterparty to the transaction;

Simeon Donev is an interested person under Article 114, paragraph 7, item 2 and item 3 of the LPOS, as on the one hand he is a Procurator of the public company “Sopharma” AD and a related party within the meaning of §1, v.13 b. d) from the RD of the LPOS with the Chairman of the Board of Directors of “Sopharma” AD Ognian Donev, and on the other hand he is a member of the Supervisory Board of the company “Telecomplex” AD - counterparty to the transaction;

Ventsislav Stoev is an interested person under Art. 114, para. 7, item 2 and item 3 of the LPOS, as on the one hand he is a related person within the meaning of §1, item 13, b. d) from the RD of LPOS with Vice Chairman of the Board of Directors of “Sopharma” AD Vessela Stoeva, and on the other hand - directly owns over 25% in the capital of “Telecomplect” AD and is a member of the Supervisory Board of the company - counterparty to the transaction;

Deputy - Chairman of the Board of Directors of “Sopharma” AD Vessela Stoeva is an interested person under Art. 114, para. 7, item 2 and item 3 of the LPOS, as a related person within the meaning of §1, item 13 b. d) to Ventsislav Stoev who directly owns over 25% of the capital of “Telecomplect” AD and is a member of the Supervisory Board of the company - counterparty to the transaction.

B) Value of the transaction:

Pursuant to Art. 114a, para. 6 of the LPOS, the sale price of the transaction is determined at market prices, in view of which the Board of Directors has accepted as fair market price of the transaction the total amount of BGN 587,954 (five hundred eighty-seven thousand nine hundred and fifty-four leva) excluding VAT and this assessment is based on a market valuation dated November 10, 2021 for each of the motor vehicles, prepared by independent licensed appraisers - consultants "MV Group" OOD, Sofia, UIC 131453430 and submitted by the SELLER - “Telecomplect” AD.

C) Assessment of the applicability of the conditions under Art. 114, para. 1, item 1 of the LPOS:
The value of the transaction does not exceed the applicable threshold under Art. 114, para 1 of LPOS, due to which the transaction falls within the scope of art. 114, para. 2.

D) Assessment of the applicability of Art. 114 para. 6 of LPOS:

With regard to this transaction, the hypothesis of Art. 114 para. 6 of LPOS does not apply.

2. “Sopharma” AD, as a BUYER, concluded a Contract for purchase and sale of movables (Sander and Paddle with hydraulic pump Spicer 1 300), owned by “Telecomplect” AD, UIC 831643753.

A) Participation of interested parties:

Ognian Donev is an interested person under Art.114, para. 7, item 2 and item 3 of the LPOS, as on the one hand he is an Chairman of the Board of Directors and represents the public company “Sopharma” AD, and on the other hand, directly owns over 25% of the capital of “Telecomplect” AD and is a member of the Supervisory Board of the company - counterparty to the transaction;

Simeon Donev is an interested person under Art. 114, para. 7, item 2 and item 3 of the LPOS, as on the one hand he is a Procurator of the public company “Sopharma” AD and a related party within the meaning of §1, v.13 b. d) from the RD of the LPOS with the Chairman of the Board of Directors of “Sopharma” AD Ognian Donev, and on the other hand he is a member of the Supervisory Board of the company “Telecomplect” AD - counterparty to the transaction;

Ventsislav Stoev is an interested person under Art. 114, para. 7, item 2 and item 3 of the LPOS, as on the one hand he is a related person within the meaning of §1, item 13, b. d) from the RD of LPOS with Vice Chairman of the Board of Directors of “Sopharma” AD Vessela Stoeva, and on the other hand - directly owns over 25% in the capital of “Telecomplect” AD and is a member of the Supervisory Board of the company - counterparty to the transaction;

Deputy - Chairman of the Board of Directors of “Sopharma” AD Vessela Stoeva is an interested person under Art. 114, para.7, item 2 and item 3 of the LPOS, as a related person within the meaning of §1, item 13 b. d) to Ventsislav Stoev who directly owns over 25% of the

capital of “Telecomplect” AD and is a member of the Supervisory Board of the company - counterparty to the transaction.

B) Value of the transaction:

Pursuant to Art. 114a, para. 6 of the LPOS, the sale price of the transaction is determined at market prices, in view of which the Board of Directors has accepted as fair market price of the transaction the total amount of BGN 24,225 (twenty-four thousand two hundred and twenty-five levs) without VAT, as indicated in a market valuation dated November 10, 2021 for each of the movables, prepared by independent licensed appraisers - consultants "MV Group" OOD, Sofia, UIC 131453430 and submitted by the SELLER - “Telecomplect” AD.

C) Assessment of the applicability of the conditions under Art. 114, para. 1, item 1 of the LPOS:

The value of the transaction does not exceed the applicable threshold under Art. 114, para 1 of LPOS, due to which the transaction falls within the scope of art. 114, para. 2.

D) Assessment of the applicability of Art. 114 para 6 of LPOS:

With regard to this transaction, the hypothesis of Art. 114 para 6 of LPOS does not apply.

10 January 2022

Sales revenues for December 2021

Sofia, Bulgaria, January 10, 2022 – According to the requirements of art. 100t of LPOS, “Sopharma” AD (SFA: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that for December 2021 the Company recorded a decrease in sales of 4% compared to the same month of the previous year, incl. 32% decrease in domestic sales and 19% increase in export sales.

For the 2021 the revenues from sales of products decrease by 3% compared to the 2020, incl. 14% increase of sales for the domestic market and 12% decrease in export sales.

13 January 2022

NOTIFICATION

Sopharma AD (the “Company”) announces that it was notified by Mr. Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to warrants in the Company:

Date of the transaction	Operation	Number of shares	Unit price (BGN)
12.01.2022	Subscription for issue of warrants completed, warrants transferred	17 340 486	0,28

14 January 2022

NOTIFICATION

“Sopharma” AD (the “Company”) announces that it was notified by “Donev Investments Holding” AD related to Ognian Donev, that “Donev Investments Holding” AD executed the following transactions related to warrants in the Company:

Date of the transaction	Operation	Number of warrants	Unit price (BGN)
12.01.2022	Subscription for issue of warrants completed, warrants transferred	17 340 486	0,28

14 January 2022

NOTIFICATION

“Sopharma” AD (the “Company”) announces that it was notified by “Telso” AD related to Vesela Stoeva, that “Telso” AD executed the following transactions related to warrants in the Company:

Date of the transaction	Operation	Number of warrants	Unit price (BGN)
12.01.2022	Subscription for issue of warrants completed, warrants transferred	8 669 359	0,28

18 January 2022

„Sopharma“ AD starts the payment of amounts from the rights with ISIN BG4000006214 sold at service auction

Sofia, Bulgaria, January 18, 2022, According to the requirements of art. 100t of LPOS, „Sopharma“ AD (the Company) (SFA: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that it starts the payment of amounts from the sale of unexercised rights with ISIN BG4000006214 at a service auction held on the “Bulgarian Stock Exchange” AD on December 6, 2021.

The amounts from the sale of the rights of shareholders with accounts with investment intermediaries have been transferred to the respective accounts, and the amounts of shareholders with personal accounts in “Central Depository” AD can be received in person after showing an identity document or by a person authorized by a notarized power of attorney at the cash desk of the Company (telephone for information 02 8134 283) at the address in Sofia, 16 Iliensko Shose Str. every working day from 10:00 a.m. to 12:00 p.m. and from 2:00 p.m. to 4:00 p.m.

For further information about the possibilities of receiving payments by bank transfer, please contact us by phone on 02 8134 319 or by e-mail at ir@sopharma.bg.

7 February 2022

Sales revenues for January 2022

Sofia, Bulgaria, February 7, 2022 – According to the requirements of art. 100t of LPOS, “Sopharma” AD (SFA: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that for January

2022 the Company recorded an increase in sales of 51% compared to the same month of the previous year, incl. normalization of domestic sales with an increase of 254% due to the low base and 35% decrease in export sales.

1 March 2022

Conclusion of transactions from the scope of art. 114, para. 2 of the LPOS

Sofia, Bulgaria, 1 March 2022 – According to the requirements of Art. 100t of LPOS and in connection with Art. 114, para. 9 of the Law on Public Offering of Securities, “Sopharma” AD (SFA: BSE-Sofia, SPH: Warsaw Stock Exchange) announces that today, according to a decision of the Board of Directors dated February 11, 2022, the company concluded the following transactions falling within the scope of Art. 114, para. 2 of the LPOS:

1. “Sopharma” AD as a Lessee, concluded Annex № 12 to the Lease Agreement dated August 8, 2012 (the “Agreement”) with “Sopharma Imoti” REIT, UIC 175059266.

A) Participation of interested parties:

Bissera Lazarova is an interested person, as on the one hand she is a member of the management body (Board of Directors) of the public company “Sopharma” AD, and on the other hand she is a member of the management body (Board of Directors) of the opposite party on the transaction - grounds for interest under Art. 114, para. 7, item 3 of the LPOS;

B) Value of the transaction:

Pursuant to Art. 114a, para. 5 of the LPOS the value of the property provided for use under the contract is determined as the higher of its market value and its value according to the last audited financial statements, which is publicly disclosed, in view of which the Board of Directors has adopted property, namely an amount in the total amount of BGN 530,360 (five hundred and thirty thousand three hundred and sixty leva), as the assessment is based on a special assessment dated October 31, 2021 for the market value of real estate, prepared by independent licensed appraisers - consultants to “Acticon” OOD, Sofia, with UIC 131359011 and presented by the Landlord – “Sopharma Imoti” REIT.

Lease term: 5 months (for the remaining term of the Contract until 01. 08. 2022);

Rental area: 312.12 sq.m.;

Rental price: 12.85 euros per sq.m. per month, without VAT.

C) Assessment of the applicability of the conditions under Art. 114, para. 1, item 1 of the LPOS:

The value of the described transaction does not exceed the threshold under Art. 114, para. 1, item 1 b. b) of the LPOS, due to which the transaction falls within the scope of Art. 114, para. 2 of LPOS and for its conclusion prior approval has been received by the Board of Directors of „Sopharma“ AD.

D) Assessment of the applicability of Art. 114 para. 6 of LPOS:

With regard to this transaction, the hypothesis of Art. 114 para. 6 of the LPOS is not applicable.

2. “Sopharma” AD, as a Lessee, concluded a Lease Agreement (the “Agreement”) with Sopharma Imoti REIT, UIC 175059266.

A) Participation of interested parties:

Bissera Lazarova is an interested person, as on the one hand she is a member of the management body (Board of Directors) of the public company “Sopharma” AD, and on the other

hand she is a member of the management body (Board of Directors) of the opposite party on the transaction - grounds for interest under Art. 114, para. 7, item 3 of the LPOS;

B) Value of the transaction:

Pursuant to Art. 114a, para. 5 of the LPOS, the value of the property provided for use under the transaction is determined as the higher of its market value and its value according to the last audited financial statements, which is publicly disclosed, in view of which the Board of Directors has adopted property, namely an amount totaling BGN 10,050 (ten thousand and fifty leva), as the assessment is based on a special assessment dated October 31, 2021 for the market value of real estate, prepared by independent licensed appraisers - consultants to "Acticon" OOD, Sofia, with UIC 131359011 and presented by the Landlord – "Sopharma Imoti" REIT.

Lease term: 10 (ten) years;

Rental area: 20.82 sq.m.;

Rental price: 4.50 euros per sq.m. per month, without VAT;

Other conditions: The rental price is updated annually as of January 1, 2023, in accordance with the Harmonized Index of Consumer Prices in the 27 EU countries (HICP EU-27) and in the event of its elimination, its replacement according to EUROSTAT index) for all goods and services for the previous year, published by EUROSTAT.

C) Assessment of the applicability of the conditions under Art. 114, para. 1, item 1 of the LPOS:

The value of the described transaction does not exceed the threshold under Art. 114, para. 1, item 1 b. b) of the LPOS, due to which the transaction falls within the scope of Art. 114, para. 2 of LPOS and for its conclusion prior approval has been received by the Board of Directors of "Sopharma" AD.

D) Assessment of the applicability of Art. 114 para 6 of LPOS:

With regard to this transaction, the hypothesis of Art. 114 para. 6 of the LPOS is not applicable.

3. Sopharma AD as a Lessee, concluded a Lease Agreement (the "Agreement") with Sopharma Imoti REIT, UIC 175059266.

A) Participation of interested parties:

Bissera Lazarova is an interested person, as on the one hand she is a member of the management body (Board of Directors) of the public company "Sopharma" AD, and on the other hand she is a member of the management body (Board of Directors) of the opposite party on the transaction - grounds for interest under Art. 114, para. 7, item 3 of the LPOS;

B) Value of the transaction:

Pursuant to Art. 114a, para. 5 of the LPOS, the value of the property provided for use under the transaction is determined as the higher of its market value and its value according to the last audited financial statement, which is publicly disclosed, in view of which the Board of Directors has adopted the property, namely an amount in the total amount of BGN 439,356.20 (four hundred and thirty-nine thousand three hundred and fifty-six and twenty hundred leva), as the assessment is based on a special assessment dated October 31, 2021 for the market value of real estate, prepared by independent licensed appraisers - consultants to "Acticon" OOD, Sofia, with UIC 131359011 and presented by the Landlord – "Sopharma Imoti" REIT.

Lease term: 10 (ten) years;

Total rental area: 68.88 sq.m.;

Rental price: 5,040 euros per month, without VAT;

C) Assessment of the applicability of the conditions under Art. 114, para. 1, item 1 of the LPOS:

The value of the described transaction does not exceed the threshold under Art. 114, para. 1, item 1 b. b) of the LPOS, due to which the transaction falls within the scope of Art. 114, para. 2 of LPOS and for its conclusion prior approval has been received by the Board of Directors of „Sopharma“ AD.

D) Assessment of the applicability of Art. 114 para. 6 of LPOS:

With regard to this transaction, the hypothesis of Art. 114 para. 6 of the LPOS is not applicable.

7 March 2022

Sales revenues for February 2022

Sofia, Bulgaria, March 7, 2022 – According to the requirements of art. 100t of LPOS, “Sopharma” AD (SFA: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that for February 2022 the Company recorded an increase in sales of 71% compared to the same month of the previous year, incl. 69% increase in domestic sales and 72% increase in export sales.

In the two months of 2022 the revenues from sales of products increase by 62%, incl. 148% increase of sales for the domestic market and 22% decrease in export sales.

5 April 2022

Sales revenues for March 2022

Sofia, Bulgaria, April 5, 2022 – According to the requirements of art. 100t of LPOS, “Sopharma” AD (SFA: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that for March 2022 the Company recorded a decrease in sales of 23% compared to the same month of the previous year, incl. 10% increase in domestic sales and 55% decrease in export sales. The reduced activity on the main foreign markets is a result of Russia's hostile invasion of Ukraine and consequently the Company's inability to maintain a normal supply of pharmaceutical, OTC and other health-related products to the countries participating in the war.

For the first quarter the revenues from sales of products increase by 29%, incl. 80% increase of sales for the domestic market and 3% decrease in export sales.

5 May 2022

Sales revenues for April 2022

Sofia, Bulgaria, May 5, 2022 – According to the requirements of art. 100t of LPOS, “Sopharma” AD (SFA: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that for April 2022 the Company recorded an increase in sales of 44% compared to the same month of the previous year, incl. 60% increase in domestic sales and 38% increase in export sales as a result of erratic recovery of activity in major foreign markets.

For the four months since the beginning of the year the revenues from sales of products increase by 34%, incl. 75% increase of sales for the domestic market and 10% increase in export sales.

2 June 2022

NOTIFICATION

“Sopharma” AD (the Company) announces that it was notified by “Donev Investments Holding” AD related to Ognian Ivanov Donev, that “Donev Investments Holding” AD executed the following transactions related to shares in the Company:

Date of the transaction	Operation	Number of shares	Unit price (BGN)
01.06.2022	Buy	5 000,00	4,46
01.06.2022	Buy	1 000,00	4,46
01.06.2022	Buy	2 900,00	4,46
01.06.2022	Buy	2 000,00	4,46
01.06.2022	Buy	1 150,00	4,46
01.06.2022	Buy	3 000,00	4,46
01.06.2022	Buy	4 144,00	4,46
01.06.2022	Buy	3 000,00	4,42

3 June 2022

Notification under Art. 111 para. 6 of LPOS for repurchase of shares

Sofia, Bulgaria, June 3, 2022 – According to the requirements of Art. 100t of LPOS, “Sopharma” AD (SFA: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that on the basis of Art. 187b of the Commercial Law and Art. 111 para. 5 and para. 6 of LPOS and in connection with a decision of the General Meeting of the company held on February 23, 2018 and a decision of the Board of Directors of June 3, 2022, “Sopharma” AD notifies that the company intends to buy its own shares in the restriction under Art. 111 para. 5 of LPOS, as follows:

- Number of shares subject to repurchase - 200,000 (two hundred thousand) shares;
- Repurchase price - BGN 4.50 per share of the company's capital;
- Repurchase date: June 6, 2022;
- Licensed investment intermediary who has been given the purchase order - "First Financial Brokerage House" OOD.

6 June 2022

NOTIFICATION

“Sopharma” AD (the Company) announces that it was notified by “Donev Investments Holding” AD related to Ognian Ivanov Donev, that “Donev Investments Holding” AD executed the following transactions related to shares in the Company:

Date of the transaction	Operation	Number of shares	Unit price (BGN)
03.06.2022	Buy	75,00	4,48

03.06.2022	Buy	4 925,00	4,48
03.06.2022	Buy	3 000,00	4,48
03.06.2022	Buy	723,00	4,48
03.06.2022	Buy	2 277,00	4,48
03.06.2022	Buy	723,00	4,48
03.06.2022	Buy	2 277,00	4,48
03.06.2022	Buy	500,00	4,48
03.06.2022	Buy	223,00	4,48
03.06.2022	Buy	400,00	4,48
03.06.2022	Buy	77,00	4,48
03.06.2022	Buy	100,00	4,46

6 June 2022

Sales revenues for May 2022

Sofia, Bulgaria, June 6, 2022 – According to the requirements of art. 100t of LPOS, “Sopharma” AD (SFA: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that for May 2022 the Company recorded an increase in sales of 16% compared to the same month of the previous year, incl. 24% decrease in domestic sales and 77% increase in export sales.

For the five months since the beginning of the year the revenues from sales of products increase by 28%, incl. 35% increase of sales for the domestic market and 24% increase in export sales.

7 June 2022

Treasury shares

Sofia, Bulgaria, June 7, 2022 - According to art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, Sopharma AD (SFA: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that on June 6, 2022 the Company bought 200 00 own shares representing 0.1484% of the share capital of the Company, at a total value of BGN 200 000,00 on the Bulgarian Stock Exchange, the average price per share was 4.500 BGN.

The total number of treasury shares after this transaction is 13 255 000, representing 9.833% of the share capital of the Company.

7 June 2022

NOTIFICATION

“Sopharma” AD (the Company) announces that it was notified by “Donev Investments Holding” AD related to Ognian Ivanov Donev, that “Donev Investments Holding” AD executed the following transactions related to shares in the Company:

Date of the transaction	Operation	Number of shares	Unit price (BGN)
-------------------------	-----------	------------------	------------------

06.06.2022	Buy	1 002,00	4,48
06.06.2022	Buy	200,00	4,48
06.06.2022	Buy	1 000,00	4,46
06.06.2022	Buy	1 000,00	4,44
06.06.2022	Buy	135,00	4,48

7 June 2022

NOTIFICATION

Sopharma AD notifies that it has received a notification from Telso AD that Telso AD has carried out the following transactions with shares of Sopharma AD:

Date of the transaction	Operation	Number of shares	Unit price (BGN)
06.06.2022	Buy	10 000,00	4,50
06.06.2022	Buy	100,00	4,48
06.06.2022	Buy	22,00	4,48
06.06.2022	Buy	4 878,00	4,48
06.06.2022	Buy	5 000,00	4,48
06.06.2022	Buy	5 000,00	4,44
06.06.2022	Buy	3 000,00	4,48
06.06.2022	Buy	865,00	4,48

8 June 2022

NOTIFICATION

Sopharma AD notifies that it has received a notification from Telso AD that Telso AD has carried out the following transactions with shares of Sopharma AD:

Date of the transaction	Operation	Number of shares	Unit price (BGN)
07.06.2022	Buy	20,00	4,50
07.06.2022	Buy	980,00	4,50
07.06.2022	Buy	100,00	4,46
07.06.2022	Buy	1 000,00	4,50
07.06.2022	Buy	2 000,00	4,50
07.06.2022	Buy	2,00	4,46
07.06.2022	Buy	20,00	4,50
07.06.2022	Buy	4 000,00	4,50
07.06.2022	Buy	980,00	4,50

10 June 2022

NOTIFICATION

Sopharma AD notifies that it has received a notification from Telso AD that Telso AD has carried out the following transactions with shares of Sopharma AD:

Date of the transaction	Operation	Number of shares	Unit price (BGN)
09.06.2022	Buy	792,00	4,44
09.06.2022	Buy	734,00	4,50
09.06.2022	Buy	1 266,00	4,50
09.06.2022	Buy	1 023,00	4,50
09.06.2022	Buy	500,00	4,48
09.06.2022	Buy	881,00	4,50
09.06.2022	Buy	394,00	4,50
09.06.2022	Buy	94,00	4,50
09.06.2022	Buy	631,00	4,50
09.06.2022	Buy	1 500,00	4,50

10 June 2022

Notification under Art. 111 para. 6 of LPOS for repurchase of shares

Sofia, Bulgaria, June 10, 2022 – According to the requirements of Art. 100t of LPOS, “Sopharma” AD (SFA: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that on the basis of Art. 187b of the Commercial Law and Art. 111 para. 5 and para. 6 of LPOS and in connection with a decision of the General Meeting of the company held on February 23, 2018 and a decision of the Board of Directors of June 3, 2022, “Sopharma” AD notifies that the company intends to buy its own shares in the restriction under Art. 111 para. 5 of LPOS, as follows:

- Number of shares subject to repurchase - 224,000 (two hundred twenty four thousand);
- Repurchase price - BGN 4.50 per share of the company's capital;
- Repurchase date: June 13, 2022;
- Licensed investment intermediary who has been given the purchase order - "First Financial Brokerage House" OOD.

13 June 2022

NOTIFICATION

Sopharma AD notifies that it has received a notification from Telso AD that Telso AD has carried out the following transactions with shares of Sopharma AD:

Date of the transaction	Operation	Number of shares	Unit price (BGN)
10.06.2022	Buy	100,00	4,48
10.06.2022	Buy	5 000,00	4,48
10.06.2022	Buy	331,00	4,50
10.06.2022	Buy	569,00	4,50
10.06.2022	Buy	4 451,00	4,50
10.06.2022	Buy	549,00	4,50
10.06.2022	Buy	1 320,00	4,50
10.06.2022	Buy	3 000,00	4,50

10.06.2022	Buy	680,00	4,50
10.06.2022	Buy	4 000,00	4,50

14 June 2022

Treasury shares

Sofia, Bulgaria, June 14, 2022 - According to art. 17 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council, Sopharma AD (SFA: "BSE-Sofia" AD, SPH: Warsaw Stock Exchange) notifies that on June 13, 2022 the Company bought 224 000 own shares representing 0.1662% of the share capital of the Company, at a total value of BGN 1 008 000,00 on the Bulgarian Stock Exchange, the average price per share was 4.500 BGN.

The total number of treasury shares after this transaction is 13 479 000, representing 9.999% of the share capital of the Company.

14 June 2022

NOTIFICATION

Sopharma AD notifies that it has received a notification from Telso AD that Telso AD has carried out the following transactions with shares of Sopharma AD:

Date of the transaction	Operation	Number of shares	Unit price (BGN)
13.06.2022	Buy	550,00	4,50
13.06.2022	Buy	4 450,00	4,50
13.06.2022	Buy	3 000,00	4,50
13.06.2022	Buy	8 000,00	4,50
13.06.2022	Buy	1 000,00	4,48
13.06.2022	Buy	180,00	4,48

15 June 2022

NOTIFICATION

Sopharma AD notifies that it has received a notification from Telso AD that Telso AD has carried out the following transactions with shares of Sopharma AD:

Date of the transaction	Operation	Number of shares	Unit price (BGN)
14.06.2022	Buy	330,00	4,50

16 June 2022

NOTIFICATION

Sopharma AD notifies that it has received a notification from Telso AD that Telso AD has carried out the following transactions with shares of Sopharma AD:

Date of the transaction	Operation	Number of shares	Unit price (BGN)
15.06.2022	Buy	1,00	4,50
15.06.2022	Buy	420,00	4,50
15.06.2022	Buy	9,00	4,50
15.06.2022	Buy	5,00	4,50
15.06.2022	Buy	1,00	4,50
15.06.2022	Buy	420,00	4,50
15.06.2022	Buy	10,00	4,50
15.06.2022	Buy	73,00	4,50
15.06.2022	Buy	330,00	4,50
15.06.2022	Buy	731,00	4,50
15.06.2022	Buy	1 950,00	4,48
15.06.2022	Buy	2 000,00	4,50
15.06.2022	Buy	266,00	4,50
15.06.2022	Buy	234,00	4,50
15.06.2022	Buy	15,00	4,48
15.06.2022	Buy	35,00	4,48
15.06.2022	Buy	61,00	4,48
15.06.2022	Buy	5 000,00	4,50
15.06.2022	Buy	4 990,00	4,50
15.06.2022	Buy	8,00	4,48
15.06.2022	Buy	4 500,00	4,50
15.06.2022	Buy	15,00	4,48

17 June 2022

NOTIFICATION

“Sopharma” AD (the Company) announces that it was notified by “Donev Investments Holding” AD related to Ognian Ivanov Donev, that “Donev Investments Holding” AD executed the following transactions related to shares in the Company:

Date of the transaction	Operation	Number of warrants	Unit price (BGN)
16.06.2022	Buy	1 000,00	0,47
16.06.2022	Buy	2 800,00	0,47
16.06.2022	Buy	20 000,00	0,47
16.06.2022	Buy	20 000,00	0,47
16.06.2022	Buy	10 000,00	0,47

17 June 2022

NOTIFICATION

Sopharma AD notifies that it has received a notification from Telso AD that Telso AD has carried out the following transactions with shares of Sopharma AD:

Date of the transaction	Operation	Number of shares	Unit price (BGN)
16.06.2022	Buy	2 216,00	4,52
16.06.2022	Buy	2 000,00	4,50
16.06.2022	Buy	3 000,00	4,50

20 June 2022

NOTIFICATION

“Sopharma” AD (the Company) announces that it was notified by “Donev Investments Holding” AD related to Ognian Ivanov Donev, that “Donev Investments Holding” AD executed the following transactions related to shares in the Company:

Date of the transaction	Operation	Number of warrants	Unit price (BGN)
17.06.2022	Buy	5 000,00	0,47
17.06.2022	Buy	5 000,00	0,47
17.06.2022	Buy	10 000,00	0,47
17.06.2022	Buy	5 000,00	0,47
17.06.2022	Buy	10 000,00	0,47

20 June 2022

NOTIFICATION

Sopharma AD notifies that it has received a notification from Telso AD that Telso AD has carried out the following transactions with shares of Sopharma AD:

Date of the transaction	Operation	Number of shares	Unit price (BGN)
17.06.2022	Buy	5 000,00	4,52
17.06.2022	Buy	5 000,00	4,52
17.06.2022	Buy	5 000,00	4,52
17.06.2022	Buy	100,00	4,52
17.06.2022	Buy	1 000,00	4,50
17.06.2022	Buy	982,00	4,50
17.06.2022	Buy	915,00	4,50
17.06.2022	Buy	2 085,00	4,50

21 June 2022

NOTIFICATION

“Sopharma” AD (the Company) announces that it was notified by “Donev Investments Holding” AD related to Ognian Ivanov Donev, that “Donev Investments Holding” AD executed the following transactions related to shares in the Company:

Date of the transaction	Operation	Number of warrants	Unit price (BGN)
20.06.2022	Buy	8 000,00	0,45
20.06.2022	Buy	20 000,00	0,43
20.06.2022	Buy	30 000,00	0,42
20.06.2022	Buy	20 000,00	0,43
20.06.2022	Buy	5 000,00	0,43
20.06.2022	Buy	5 000,00	0,43

21 June 2022

NOTIFICATION

Sopharma AD notifies that it has received a notification from Telso AD that Telso AD has carried out the following transactions with shares of Sopharma AD:

Date of the transaction	Operation	Number of warrants	Unit price (BGN)
20.06.2022	Sell	2 000,00	0,45
20.06.2022	Sell	8 000,00	0,45
20.06.2022	Sell	20 000,00	0,43
20.06.2022	Sell	30 000,00	0,42
20.06.2022	Sell	20 000,00	0,43
20.06.2022	Sell	5 000,00	0,42
20.06.2022	Sell	5 000,00	0,43
20.06.2022	Sell	5 000,00	0,43

21 June 2022

NOTIFICATION

“Sopharma” AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date of the transaction	Operation	Number of warrants	Unit price (BGN)
20.06.2022	Buy	5,000	0,42

22 June 2022

NOTIFICATION

“Sopharma” AD (the Company) announces that it was notified by “Donev Investments Holding” AD related to Ognian Ivanov Donev, that “Donev Investments Holding” AD executed the following transactions related to shares in the Company:

Date of the transaction	Operation	Number of warrants	Unit price (BGN)
21.06.2022	Buy	10 000,00	0,43
21.06.2022	Buy	10 000,00	0,43
21.06.2022	Buy	10 000,00	0,43
21.06.2022	Buy	10 000,00	0,42
21.06.2022	Buy	10 000,00	0,42
21.06.2022	Buy	10 000,00	0,42

22 June 2022

NOTIFICATION

Sopharma AD notifies that it has received a notification from Telso AD that Telso AD has carried out the following transactions with shares of Sopharma AD:

Date of the transaction	Operation	Number of warrants	Unit price (BGN)
20.06.2022	Sell	10 000,00	0,43
20.06.2022	Sell	10 000,00	0,43
20.06.2022	Sell	10 000,00	0,43
20.06.2022	Sell	10 000,00	0,42
20.06.2022	Sell	10 000,00	0,42
20.06.2022	Sell	10 000,00	0,42

23 June 2022

NOTIFICATION

“Sopharma” AD (the Company) announces that it was notified by “Donev Investments Holding” AD related to Ognian Ivanov Donev, that “Donev Investments Holding” AD executed the following transactions related to shares in the Company:

Date of the transaction	Operation	Number of warrants	Unit price (BGN)
22.06.2022	Buy	10 000,00	0,41
22.06.2022	Buy	5 000,00	0,45

23 June 2022

NOTIFICATION

Sopharma AD notifies that it has received a notification from Telso AD that Telso AD has carried out the following transactions with shares of Sopharma AD:

Date of the transaction	Operation	Number of warrants	Unit price (BGN)
22.06.2022	Sell	1 000,00	0,42
22.06.2022	Sell	30 000,00	0,41
22.06.2022	Sell	10 000,00	0,41

24 June 2022

NOTIFICATION

“Sopharma” AD (the Company) announces that it was notified by “Donev Investments Holding” AD related to Ognian Ivanov Donev, that “Donev Investments Holding” AD executed the following transactions related to shares in the Company:

Date of the transaction	Operation	Number of warrants	Unit price (BGN)
23.06.2022	Buy	4 000,00	0,42
23.06.2022	Buy	4 000,00	0,42
23.06.2022	Buy	2 000,00	0,42

24 June 2022

NOTIFICATION

Sopharma AD notifies that it has received a notification from Telso AD that Telso AD has carried out the following transactions with shares of Sopharma AD:

Date of the transaction	Operation	Number of warrants	Unit price (BGN)
23.06.2022	Sell	4 000,00	0,42
23.06.2022	Sell	4 000,00	0,42
23.06.2022	Sell	2 000,00	0,42

27 June 2022

NOTIFICATION

“Sopharma” AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date of the transaction	Operation	Number of warrants	Unit price (BGN)
24.06.2022	Buy	600	0,43
24.06.2022	Buy	5 000	0,43
24.06.2022	Buy	5 000	0,43
24.06.2022	Buy	2 000	0,45
24.06.2022	Buy	5 000	0,45

27 June 2022

NOTIFICATION

“Sopharma” AD (the Company) announces that it was notified by “Donev Investments Holding” AD related to Ognian Ivanov Donev, that “Donev Investments Holding” AD executed the following transactions related to shares in the Company:

Date of the transaction	Operation	Number of warrants	Unit price (BGN)
24.06.2022	Buy	10 000,00	0,42
24.06.2022	Buy	3 000,00	0,45

27 June 2022

NOTIFICATION

Sopharma AD notifies that it has received a notification from Telso AD that Telso AD has carried out the following transactions with shares of Sopharma AD:

Date of the transaction	Operation	Number of warrants	Unit price (BGN)
24.06.2022	Sell	10 000,00	0,42

28 June 2022

NOTIFICATION

“Sopharma” AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date of the transaction	Operation	Number of warrants	Unit price (BGN)
27.06.2022	Buy	5 000	0,45
27.06.2022	Buy	5 000	0,45
27.06.2022	Buy	5 000	0,45
27.06.2022	Buy	5 000	0,45
27.06.2022	Buy	26 000	0,43
27.06.2022	Buy	24 000	0,43

27.06.2022	Buy	10 000	0,41
27.06.2022	Buy	5 000	0,41
27.06.2022	Buy	5 000	0,45

28 June 2022

NOTIFICATION

“Sopharma” AD (the Company) announces that it was notified by “Donev Investments Holding” AD related to Ognian Ivanov Donev, that “Donev Investments Holding” AD executed the following transactions related to shares in the Company:

Date of the transaction	Operation	Number of warrants	Unit price (BGN)
24.06.2022	Buy	5 000,00	0,45
24.06.2022	Buy	750,00	0,45

28 June 2022

NOTIFICATION

Sopharma AD notifies that it has received a notification from Telso AD that Telso AD has carried out the following transactions with shares of Sopharma AD:

Date of the transaction	Operation	Number of warrants	Unit price (BGN)
27.06.2022	Sell	5 000,00	0,45
27.06.2022	Sell	5 000,00	0,45
27.06.2022	Sell	1 500,00	0,43
27.06.2022	Sell	2 500,00	0,43
27.06.2022	Sell	26 000,00	0,43
27.06.2022	Sell	24 000,00	0,43
27.06.2022	Sell	10 000,00	0,41
27.06.2022	Sell	5 000,00	0,41

29 June 2022

NOTIFICATION

“Sopharma” AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date of the transaction	Operation	Number of shares	Unit price (BGN)
28.06.2022	Buy	5 000	0,45
28.06.2022	Buy	5 000	0,45
28.06.2022	Buy	3 000	0,45

28.06.2022	Buy	5 000	0,45
28.06.2022	Buy	5 000	0,43
28.06.2022	Buy	50 000	0,43
28.06.2022	Buy	5 000	0,45
28.06.2022	Buy	5 000	0,45
28.06.2022	Buy	5 000	0,45
28.06.2022	Buy	5 000	0,43
28.06.2022	Buy	5 000	0,43
28.06.2022	Buy	45 000	0,43
28.06.2022	Buy	5 000	0,45
28.06.2022	Buy	5 000	0,45
28.06.2022	Buy	5 000	0,43
28.06.2022	Buy	5 000	0,45
28.06.2022	Buy	5 000	0,45
28.06.2022	Buy	1 500	0,45

29 June 2022

NOTIFICATION

“Sopharma” AD (the Company) announces that it was notified by “Donev Investments Holding” AD related to Ognian Ivanov Donev, that “Donev Investments Holding” AD executed the following transactions related to shares in the Company:

Date of the transaction	Operation	Number of warrants	Unit price (BGN)
28.06.2022	Buy	1 000,00	0,43
28.06.2022	Buy	4 000,00	0,43
28.06.2022	Buy	3 000,00	0,43
28.06.2022	Buy	1 500,00	0,43

29 June 2022

NOTIFICATION

Sopharma AD notifies that it has received a notification from Telso AD that Telso AD has carried out the following transactions with shares of Sopharma AD:

Date of the transaction	Operation	Number of warrants	Unit price (BGN)
28.06.2022	Sell	1 000,00	0,43
28.06.2022	Sell	4 000,00	0,43
28.06.2022	Sell	3 000,00	0,43
28.06.2022	Sell	5 000,00	0,43
28.06.2022	Sell	3 000,00	0,43
28.06.2022	Sell	50 000,00	0,43
28.06.2022	Sell	1 500,00	0,43
28.06.2022	Sell	5 000,00	0,43

28.06.2022	Sell	5 000,00	0,43
28.06.2022	Sell	5 000,00	0,43
28.06.2022	Sell	45 000,00	0,43
28.06.2022	Sell	5 000,00	0,43

30 June 2022

NOTIFICATION

“Sopharma” AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date of the transaction	Operation	Number of shares	Unit price (BGN)
29.06.2022	Buy	5 000	0,45
29.06.2022	Buy	5 000	0,44
29.06.2022	Buy	5 000	0,44
29.06.2022	Buy	5 000	0,45
29.06.2022	Buy	5 000	0,45
29.06.2022	Buy	5 000	0,45
29.06.2022	Buy	5 000	0,45

30 June 2022

NOTIFICATION

Sopharma AD notifies that it has received a notification from Telso AD that Telso AD has carried out the following transactions with shares of Sopharma AD:

Date of the transaction	Operation	Number of warrants	Unit price (BGN)
29.06.2022	Sell	5 000,00	0,44
29.06.2022	Sell	5 000,00	0,44

1 July 2022

NOTIFICATION

“Sopharma” AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

Date of the transaction	Operation	Number of warrants	Unit price (BGN)
30.06.2022	Buy	3 090	0,45
30.06.2022	Buy	1 910	0,45
30.06.2022	Buy	3 090	0,45
30.06.2022	Buy	6 910	0,45
30.06.2022	Buy	3 890	0,45
30.06.2022	Buy	5 000	0,45

30.06.2022	Buy	4 986	0,45
30.06.2022	Buy	20 000	0,43
30.06.2022	Buy	50 000	0,43
30.06.2022	Buy	5 000	0,45
30.06.2022	Buy	5 000	0,43
30.06.2022	Buy	5 000	0,45
30.06.2022	Buy	3 000	0,44
30.06.2022	Buy	4 000	0,46
30.06.2022	Buy	1 367	0,46
30.06.2022	Buy	1 000	0,46

1 July 2022

NOTIFICATION

“Sopharma” AD (the Company) announces that it was notified by “Donev Investments Holding” AD related to Ognian Ivanov Donev, that “Donev Investments Holding” AD executed the following transactions related to shares in the Company:

Date of the transaction	Operation	Number of warrants	Unit price (BGN)
30.06.2022	Buy	5 000,00	0,45
30.06.2022	Buy	10 000,00	0,43
30.06.2022	Buy	2 000,00	0,44
30.06.2022	Buy	1 500,00	0,46
30.06.2022	Buy	5 000,00	0,46

1 July 2022

NOTIFICATION

Sopharma AD notifies that it has received a notification from Telso AD that Telso AD has carried out the following transactions with shares of Sopharma AD:

Date of the transaction	Operation	Number of warrants	Unit price (BGN)
30.06.2022	Sell	2 000,00	0,43
30.06.2022	Sell	20 000,00	0,43
30.06.2022	Sell	10 000,00	0,43
30.06.2022	Sell	2 000,00	0,44
30.06.2022	Sell	50 000,00	0,43
30.06.2022	Sell	5 000,00	0,43
30.06.2022	Sell	3 000,00	0,44

5 July 2022

Sales revenues for June 2022

Sofia, Bulgaria, July 5, 2022 – According to the requirements of art. 100t of LPOS, “Sopharma” AD (SFA: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that for June 2022 the Company recorded an increase in sales of 83% compared to the same month of the previous year, incl. 39% increase in domestic sales and 109% increase in export sales.

For the six months since the beginning of the year the revenues from sales of products increase by 37%, incl. 35% increase of sales for the domestic market and 38% increase in export sales.

7 July 2022

The Board of Directors of “Sopharma” AD adopted a decision to issue a second warrants issue

Sofia, Bulgaria, July 7, 2022 – According to the requirements of art. 100t of LPOS, “Sopharma” AD (SFA: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that in accordance with art. 25 of the Articles of incorporation of the Company, the Board of Directors adopted a decision for issuance, under the conditions of initial public offering, of warrants as follows:

Exercise price: BGN 6.10

Issuance price of one warrant: BGN 0.48

Number of warrants: 26 959 580

Minimum success threshold of the issue: 13 479 790

Term in which the right can be exercised: 5 years

The remaining parameters of the issue will be described in a Prospectus for Public Offering of warrants, which should be adopted by the Board of Directors with a subsequent decision and should receive the relevant approval from the Bulgarian Financial Supervision Commission.

The consultant and investment intermediary selected by the Board of Directors in connection with the issuance of the warrants are respectively: Main Capital AD, UIC 202402882, with registered office in Sofia, and management address Sofia 1404, Triaditsa District, zh.k. “Gotse Delchev”, bl. 22, entrance 2 and MK Brokers AD, UIC 175007052, with registered office in Sofia and management address, 8, “Tsar Osvoboditel” Blvd.

29 July 2022

Inside information under art. 17, para 1, in relation with art. 7 of the Regulation (EU) No 596/2014

Sofia, Bulgaria, July 29, 2022 – According to the requirements of art. 154, para 1 of LPOS and art. 36 from Ordinance 13 as of 22.12.2003, “Sopharma” AD (SFA: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that at with letter 15-00-6/28.07.2022 the Financial Supervision Commission advised “Sopharma” AD that the Commission does not issue a final prohibition on the publication of a corrected tender offering by “Sopharma” AD, for the purchase through investment intermediary MK Brokers AD of 14,632,655 shares (66.66%) of the capital of "Sopharma Properties" REIT from the remaining shareholders of the company.

In connection with the above and in accordance with the provisions of Art. 154, para. 1 of the LPOS, Sopharma AD publishes the Tender Offering to the shareholders of "Sopharma Properties" REIT, the essential conditions of which in summary are as follows:

1. Information about offeror

The offeror is "Sopharma" AD, a company with public status within the meaning of Art. 110, para. 1 of the Law on the Public Offering of Securities, established in the Republic of Bulgaria and entered in the Commercial Register maintained by the Registration Agency, with the company name "Sopharma" AD, EIK 831902088, with headquarters and management address: Sofia, district Nadezhda, ul. Iliensko shose No. 16, LEI code 097900BGGW0000048796.

According to Art. 5 of the Articles of Association of the Company, the subject of activity of "Sopharma" AD is: production of medicines and chemical-pharmaceutical preparations, commercial activity in the country and abroad, scientific and research activity in the field of phytochemistry, chemistry and pharmaceuticals.

As of the date of registration of the Tender Offering, Sopharma AD has capital in the amount of BGN 134,797,899, which is fully paid.

2. The offered price per share from the offeror is BGN 8.20.

3. The number of shares that the offeror does not own and is obliged to request to acquire is 14,632,655 shares, representing 66.66% of the capital and votes in the general meeting of "Sopharma Properties" REIT.

4. The Offeror has no intention of changing the capital of the Company within three years from the completion of the Tender Offering. The intentions of the offeror are to preserve the main activity of "Sopharma Properties" REIT in the next 5-8 years. The offeror does not declare any intention to make changes in the structure of the Company. No changes are foreseen in the composition of the Board of Directors or the personnel of the Company three years after the completion of the tender offer.

5. The evaluation of the price per share in summary is as follows:

a. The price offered by the offeror is BGN 8.20 per share.

b. The calculated fair price of the shares is BGN 6.23 per share.

c. The value, according to the valuation methods used, is as follows:

Table No 1 Evaluation methods

Evaluation method	Value	Weight
-------------------	-------	--------

Discounted dividends	4.66	20.0%
----------------------	------	-------

Net asset value	3.42	20.0%
-----------------	------	-------

Peers	5.09	60.0%
-------	------	-------

Value per share 4.67 100.0%

Source: "Mane Capital"

Table No. 2 Evaluation according to Art. 5 of Ordinance No. 41

Method	Value	Weight
--------	-------	--------

Value according to the evaluation methods	4.67	20.0%
---	------	-------

Weighted Average price for the last 6 months	6.62	80.0%
--	------	-------

Value per share 6.23 100.0%

Source: "Mane Capital"

d. According to a report issued by the Bulgarian Stock Exchange AD, the weighted average market price in the last six months was BGN6,616 per share.

e. Information on whether the company is actively traded

Table No3 Trade data

In accordance with art. 36, para 3 of Ordinance 13 as of 22.12.2003, Sopharma AD advises all interested parties that the final version of the Tender offering can be found on the platform <https://www.x3news.com/> and on the Company's webs

5 August 2022

Sales revenues for July 2022

Sofia, Bulgaria, August 5, 2022 – According to the requirements of art. 100t of LPOS, “Sopharma” AD (SFA: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that for July 2022 the Company recorded an increase in sales of 146% compared to the same month of the previous year, incl. 96% increase in domestic sales and 206% increase in export sales.

For the seven months since the beginning of the year the revenues from sales of products increase by 46%, incl. 42% increase of sales for the domestic market and 49% increase in export sales.

26 August 2022

Results of the tender offering extended to the shareholders of “Sopharma Properties” REIT

Sofia, Bulgaria, August 26, 2022 – According to the requirements of art. 100t of LPOS, “Sopharma” AD (SFA: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that as a result of the tender offering extended to the shareholders of "Sopharma Imoti" REIT, "Sopharma" AD will directly own 7 788 145 shares of the capital of "Sopharma Imoti" REIT, representing 35.48 % of the capital of "Sopharma Imoti" REIT.

The tender offer was accepted by 24 shareholders, owning a total of 469 480 shares of the capital "Sopharma Imoti" REIT.

7 September 2022

Sales revenues for August 2022

Sofia, Bulgaria, September 7, 2022 – According to the requirements of art. 100t of LPOS, “Sopharma” AD (SFA: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that for August 2022 the Company recorded a decrease in sales of 12% compared to the same month of the previous year, incl. 6% increase in domestic sales and 21% decrease in export sales.

For the eight months since the beginning of the year the revenues from sales of products increase by 35%, incl. 37% increase of sales for the domestic market and 35% increase in export sales.

27 September 2022

NOTIFICATION

“Sopharma” AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to warrants in the Company:

Date of the transaction	Operation	Number of warrants	Unit price (BGN)
26.09.2022	Buy	4 000	0,51
26.09.2022	Buy	4 000	0,51
26.09.2022	Buy	2 000	0,51
26.09.2022	Buy	4 000	0,51
26.09.2022	Buy	2 000	0,55
26.09.2022	Buy	8 000	0,55
26.09.2022	Buy	5 000	0,52
26.09.2022	Buy	1 526	0,52
26.09.2022	Buy	8 000	0,52
26.09.2022	Buy	474	0,52
26.09.2022	Buy	5 000	0,52
26.09.2022	Buy	263	0,57
26.09.2022	Buy	8 000	0,52

28 September 2022

NOTIFICATION

“Sopharma” AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to warrants in the Company:

Date of the transaction	Operation	Number of warrants	Unit price (BGN)
27.06.2022	Buy	3 000	0,51
27.06.2022	Buy	26 937	0,55
27.06.2022	Buy	63	0,55

28 September 2022

NOTIFICATION

Sopharma AD notifies that it has received a notification from Telso AD that Telso AD has carried out the following transactions with shares of Sopharma AD:

Date and time of the transaction	Operation	Number of shares	Unit price (BGN)
27.09.2022	Buy	1 482,00	4,50
27.09.2022	Buy	2 000,00	4,50
27.09.2022	Buy	44,00	4,50
27.09.2022	Buy	2 500,00	4,50

27.09.2022	Buy	3 000,00	4,50
------------	-----	----------	------

29 September 2022

Shareholding notification from “Telso” AD

Sofia, Bulgaria, September 29, 2022 – According to the requirements of Art. 148b and Art. 100t of LPOS, “Sopharma” AD (SFA: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that the Company received a shareholding notification from “Telso” AD, UIC 131176385 for a transaction with shares of the Company with settlement on September 29, 2022 with which “Telso” AD reaches 5% in the capital of “Sopharma” AD.

29 September 2022

NOTIFICATION

Sopharma AD notifies that it has received a notification from Telso AD that Telso AD has carried out the following transactions with warrants of Sopharma AD:

Date and time of the transaction	Operation	Number of варанти	Unit price (BGN)
26.09.2022	Sell	5 000,00	0,52
26.09.2022	Sell	1 526,00	0,52

29 September 2022

NOTIFICATION

“Sopharma” AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to warrants in the Company:

Date of the transaction	Operation	Number of warrants	Unit price (BGN)
28.06.2022	Buy	2 000	0,54
28.06.2022	Buy	5 000	0,52
28.06.2022	Buy	5 000	0,52

29 September 2022

NOTIFICATION

Sopharma AD notifies that it has received a notification from Telso AD that Telso AD has carried out the following transactions with warrants of Sopharma AD:

Date and time of the transaction	Operation	Number of shares	Unit price (BGN)
---	------------------	-------------------------	-----------------------------

3 October 2022

NOTIFICATION

“Sopharma” AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to warrants in the Company:

Date of the transaction	Operation	Number of warrants	Unit price (BGN)
30.09.2022	Buy	3 500	0,53

3 October 2022

NOTIFICATION

Sopharma AD notifies that it has received a notification from Telso AD that Telso AD has carried out the following transactions with warrants of Sopharma AD:

Date and time of the transaction	Operation	Number of shares	Unit price (BGN)
30.09.2022	Buy	5 000,00	4,50
30.09.2022	Buy	5 000,00	4,50
30.09.2022	Buy	5 000,00	4,50
30.09.2022	Buy	5 000,00	4,50
30.09.2022	Buy	5 000,00	4,50
30.09.2022	Buy	5 000,00	4,50
30.09.2022	Buy	1 000,00	4,46
30.09.2022	Buy	5 000,00	4,50
30.09.2022	Buy	5 000,00	4,50
30.09.2022	Buy	5 000,00	4,50
30.09.2022	Buy	5 000,00	4,50
30.09.2022	Buy	5 000,00	4,50
30.09.2022	Buy	5 000,00	4,50
30.09.2022	Buy	2 500,00	4,50
30.09.2022	Buy	2 500,00	4,50
30.09.2022	Buy	5 000,00	4,50
30.09.2022	Buy	5 000,00	4,50
30.09.2022	Buy	5 000,00	4,50
30.09.2022	Buy	5 000,00	4,50
30.09.2022	Buy	5 000,00	4,50
30.09.2022	Buy	5 000,00	4,50
30.09.2022	Buy	5 000,00	4,50
30.09.2022	Buy	5 000,00	4,50
30.09.2022	Buy	5 000,00	4,50
30.09.2022	Buy	2 000,00	4,50
30.09.2022	Buy	5 000,00	4,50
30.09.2022	Buy	250,00	4,50
30.09.2022	Buy	200,00	4,50

5 October 2022

Sales revenues for September 2022

Sofia, Bulgaria, October 5, 2022 – According to the requirements of art. 100t of LPOS, “Sopharma” AD (SFA: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that for September 2022 the Company recorded a decrease in sales of 36% compared to the same month of the previous year, incl. 54% decrease in domestic sales and 23% decrease in export sales.

For the nine months since the beginning of the year the revenues from sales of products increase by 20%, incl. 17% increase of sales for the domestic market and 23% increase in export sales.

26 October 2022

Merger of the subsidiary "Biopharm-engineering" AD into "Sopharma" AD

Sofia, Bulgaria, October 26, 2022 – According to the requirements of art. 100t of LPOS, “Sopharma” AD (SFA: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that the Board of Directors of "Sopharma" AD adopted a decision to initiate a procedure for the merger of the subsidiary "Biopharm-Engineering" AD, UIC: 119055339 in "Sopharma" AD under the conditions and in accordance with Chapter XVI of the Commercial Law and Art. 122 of the Law on the Public Offering of Securities. At the start of the procedure Sopharma AD owns 97.15% in the capital of the company.

7 November 2022

Sales revenues for October 2022

Sofia, Bulgaria, November 7, 2022 – According to the requirements of art. 100t of LPOS, “Sopharma” AD (SFA: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that for October 2022 the Company recorded a increase in sales of 30% compared to the same month of the previous year, incl. 13% decrease in domestic sales and 58% increase in export sales.

For the ten months since the beginning of the year the revenues from sales of products increase by 19%, incl. 12% increase of sales for the domestic market and 23% increase in export sales.

28 November 2022

Tender offer to the shareholders of “Sopharma” AD by “Donev Investments Holding” AD

Sofia, Bulgaria, November 28, 2022 - According to the requirements of Art. 100t of the LPOS, the Board of Directors of "Sopharma" AD (SFA: "BFB - Sofia", SPH: Warsaw Stock Exchange) announces that on November 28, 2022, "Sopharma" AD received a tender offer registered with the Commission for Financial Supervision from "DONEV INVESTMENTS HOLDING" AD - a shareholder, directly owning 37,600,000 ordinary, dematerialized shares with voting rights, representing 27.89% of the capital and votes in the GMS of "SOPHARMA" AD, on the basis of Art. 149b of the Law on the Public Offering of Securities for the purchase of shares from the remaining shareholders of "SOPHARMA" AD.

The material terms of the tender offering are:

Information on the trading offeror:

The Offeror is "DONEV INVESTMENTS HOLDING" AD, a company established and operating as a joint stock company under Bulgarian law, with its registered office and registered address in Sofia, 1000, Vazrazhdane district, 12, Positano Str.; phone: +359 (2) 9880016; electronic address (e-mail) ivandonev@di.h.bg; electronic web-site: none. "DONEV INVESTMENTS HOLDING" AD is entered in the Commercial Register and the Register of Non-Profit Legal Entities maintained by the Registry Agency ("Commercial Register") with UIC 831915121.

The main activities of Offeror are as follows: participation in the capital of other commercial companies; acquisition and management of investments in other companies; acquisition of financial assets for the purpose of trading, raising of funds by issuing securities and subsequent investment of the funds raised, investment management and investment operations, consultancy services, translation activities and all activities in the territory of the country or abroad not prohibited by law.

The name of the Offeror is "DONEV INVESTMENTS HOLDING" AD. The company was incorporated under the name "Sofia" AD, and subsequently on 14.05.2008, the current name of the company - "DONEV INVESTMENTS HOLDING" AD - was entered in the Commercial Register at the Registration Agency.

As of the date of registration of the Tender Offer, "DONEV INVESTMENTS HOLDING" AD has capital in the amount of BGN 25 000 000, which is fully paid. The Legal Entity Identifier code is 529900M68G247LNXVB33.

"DONEV INVESTMENTS HOLDING" AD is managed by a Board of Directors (BoD) composed of:

- PhD Ognian Ivanov DONEV, business address Sofia, 1000, Vazrazhdane district, 12, Positano Str. - Chairman of the Board of Directors;
- Ivan Ognianov Donev, business address Sofia, 1000, Vazrazhdane district, 12, Positano Str.- Member of the Board of Directors and Executive Director;
- Rositsa Dimcheva DONEVA, business address Sofia, 1000, Vazrazhdane district, 12, Positano Str.- Member of the Board of Directors.

In accordance with its Articles of Association, "DONEV INVESTMENTS HOLDING" AD is represented by its Executive Director - Ivan Ognianov Donev.

Shareholders holding directly and/or through related parties more than 5 per cent of the votes in the General Meeting of the Offeror are as follows:

PhD Ognian Ivanov Donev - shareholder, directly holding 24 846 300 shares or 99.385% of the capital and votes in the GMS of "DONEV INVESTMENTS HOLDING" AD.

The business address of Mr. Ognian Ivanov Donev is Sofia, 1000, Vazrazhdane district, 12, Positano Str.- Chairman of the Board of Directors;

PhD Ognian Ivanov Donev exercises control over "DONEV INVESTMENTS HOLDING" AD within the meaning of §1c, item 1 of the Additional Provisions of the Commercial Act and §1, item 14 of the Additional Provisions of the Law on Public Offering of Securities, as he directly holds more than 50 percent of the votes in the General Meeting of Shareholders of "DONEV INVESTMENTS HOLDING" AD.

Number of voting shares that the offeror does not own

"DONEV INVESTMENTS HOLDING" AD does not own (directly, through related parties or indirectly under Article 149, paragraph 2 of LPOS) 89 865 700 ordinary, dematerialised, registered, freely transferable shares with ISIN BG11SOSOBT18, representing 66.67% of the capital and of the votes at the General Meeting of Shareholders of "SOPHARMA" AD. In accordance with a resolution of the Board of Directors of the Offeror dated 28.10.2022, the Offeror intends to increase its stake in the Company's capital by acquiring

directly and through related parties more than 1/3, i. e. up to 41.49% of the votes in the General Meeting of Shareholders of the Company, by way of purchase under the Tender Offering pursuant to Art. 149b of the LPOS, addressed to all other shareholders of “SOPHARMA” AD for up to 11 000 000 ordinary, dematerialised, registered, freely transferable shares, with ISIN BG11SOSOBT18, representing 8.16% of the capital and votes in the General Meeting of Shareholders of “SOPHARMA” AD.

The strategic plans of the Offeror for “Sopharma” AD

According to the information presented in the Tender Offering, the Offeror's strategic plan for “Sopharma” AD (the Company) includes the following key points:

- increase sales of its existing portfolio and adding new products in therapeutic groups in which the Company has strategic interest. To this end, the company is actively exploring various acquisition opportunities that would complement and diversify its portfolio;
- achieve a phased transformation of its production processes and facilities by optimising the Company's production capacity through the purchase and modernisation of new machinery and equipment and the transfer of production activities and technologies. In addition, a strategy has been developed and is in the process of being implemented to optimize the planning, procurement, production, distribution processes through active supply chain management. This would also allow new business segments to develop, such as potentially contract manufacturing;
- the continued operation of production in full compliance with EU Good Manufacturing Practices;
- diversify its distribution business, which is carried out through its subsidiary “SOPHARMA TRADING” AD. In 2015, “SOPHARMA TRADING” AD launched the development of its own retail pharmacy concept under the SOpharmacy brand. In 2017, the company acquired a chain of pharmacies "PharmaStor", which subsequently went under the SOpharmacy brand. In October 2020, the Company acquired the companies of the SCS Franchise Group AD as well as Sanita Franchising AD. As a result of the transaction, “SOPHARMA TRADING” AD acquired over 150 pharmacies across the country under the Sanita, Seiba and SCS brands. The plans foresee their transition under the SOpharmacy brand, a process that began in 2021. In the future, “SOPHARMA TRADING” AD aims to continue to strengthen its position on the Bulgarian market by expanding its pharmacy network in the country;
- implement new technologies to support the automation of business processes in the SOPHARMA GROUP (the "Group");
- deepen operational synergies between Group companies, both within segments and between interrelated segments such as pharmaceutical manufacturing and distribution;
- develop its staff through training to enhance their qualifications and competencies and to maintain and sustain its reputation as an employer of choice with career development opportunities in the Group's segments, as well as to work closely with specialist higher education institutions and offer career start-up opportunities to staff;
- implement a diversity policy within the Group in order to create a work environment free from prejudice, cultivate an atmosphere of respect and mutual trust, nurture a corporate culture with mutual respect and value for each individual. Managers and employees shall conduct their business professionally, impartially, with dignity and integrity, avoiding conflicts of interest;
- implement a green policy to reduce the carbon footprint of the Group's companies through the use of renewable energy.

The implementation of the strategy depends on the impact and development of the following main risk factors, typical for the profile of “SOPHARMA” AD and the businesses in which the Group companies operate:

- non-systemic risks specific to the Group - risks from the impact of epidemics and pandemics; risks arising from dependence on the development of the world economy and trade; risk of political instability in traditional markets and regions, military action and/or sanctions; fraud and abuse risks; risks related to the regulatory framework governing the pharmaceutical business and environmental protection; risks related to attracting and retaining experienced and skilled staff; credit, liquidity, currency and interest rate risk. Each of these risks affects the Group's segments to varying degrees;
- systemic risks related to the market and macro environment in which the companies operate. These risks cannot be managed and controlled by the Group.

The Proposal is not expected to have an impact on the employees of “SOPHARMA” AD (including the employees of its subsidiaries) and “DONEV INVESTMENTS HOLDING” AD for a period of three years following the closing of the transaction. No change of the place of business of “SOPHARMA” AD (including its subsidiaries) and “DONEV INVESTMENTS HOLDING” AD is envisaged.

Offer price per share

The proposed price is BGN 4.50 per share and is higher than the weighted average market price of the shares for the last 6 months, prior to the registration of the Tender Offer, which amounted to BGN 4.485.

Any shareholder - addressee of the offer may accept it within the period specified therein by submitting an application for acceptance in the form. The price of the purchased shares shall be paid by the trading offeror, through the investment intermediary Karoll AD within 7 working days after the expiry of the deadline for acceptance of the offer, according to the instructions for the method of payment by the shareholder who accepted the offer.

29 November 2022

Conclusion of transactions from the scope of art. 114, para. 2 of the LPOS

Sofia, Bulgaria, 29 November 2022 – According to the requirements of Art. 100t of LPOS and in connection with Art. 114, para. 9 of the Law on Public Offering of Securities, “Sopharma” AD (SFA: BSE-Sofia, SPH: Warsaw Stock Exchange) announces that today, according to a decision of the Board of Directors dated November 28, 2022, the company concluded the following transaction falling within the scope of Art. 114, para. 2 of the LPOS:

1. “Sopharma” AD as a Lessee, concluded Annex № 1 to the Lease Agreement dated March 1, 2022 with “Sopharma Imoti” REIT, UIC 175059266.

A) Participation of interested parties:

Bissera Lazarova is an interested person, as on the one hand she is a member of the management body (Board of Directors) of the public company “Sopharma” AD, and on the other hand she is a member of the management body (Board of Directors) of the opposite party on the transaction - grounds for interest under Art. 114, para. 7, item 3 of the LPOS;

B) Value of the transaction:

Pursuant to Art. 114a, para. 5 of the LPOS the value of the property provided for use under the contract is determined between the higher of its market value and its value according to the

last audited financial statements, which is publicly disclosed, in view of which the Board of Directors has adopted property, namely an amount in the total amount of BGN 8,150 (eight thousand one hundred and fifty leva), as the assessment is based on a special assessment dated October 10, 2022 for the market value of real estate, prepared by independent licensed appraisers - consultants to "Acticon" OOD, Sofia, with UIC 131359011 and presented by the Landlord – "Sopharma Imoti" REIT.

Lease term: 9 years and 2 months (for the remaining term of the Contract until 01.03.2032);

Rental area: 15.76 sq.m.;

Rental price: 4.85 euros per sq.m. per month, without VAT.

C) Assessment of the applicability of the conditions under Art. 114, para. 1, item 1 of the LPOS:

The value of the described transaction does not exceed the threshold under Art. 114, para. 1, item 1 b. b) of the LPOS, due to which the transaction falls within the scope of Art. 114, para. 2 of LPOS and for its conclusion prior approval has been received by the Board of Directors of „Sopharma“ AD.

D) Assessment of the applicability of Art. 114 para. 6 of LPOS:

With regard to this transaction, the hypothesis of Art. 114 para. 6 of the LPOS is not applicable.

2 December 2022

NOTIFICATION

“Sopharma” AD notifies that it has received a notification from “Telso” AD that “Telso” AD has carried out the following transactions with shares of “Sopharma” AD:

Date and time of the transaction	Operation	Number of shares	Unit price (BGN)
01.12.2022	Buy	400,00	4,50
01.12.2022	Buy	63,00	4,50
01.12.2022	Buy	1 537,00	4,50
01.12.2022	Buy	463,00	4,50
01.12.2022	Buy	537,00	4,50
01.12.2022	Buy	500,00	4,50
01.12.2022	Buy	1 007,00	4,50
01.12.2022	Buy	993,00	4,50

2 December 2022

NOTIFICATION

“Sopharma” AD notifies that it has received a notification from “Telso” AD that “Telso” AD has carried out the following transactions with warrants of “Sopharma” AD:

Date and time of the transaction	Operation	Number of warrants	Unit price (BGN)
01.12.2022	Sell	2 430,00	0,53
01.12.2022	Sell	1 500,00	0,53

01.12.2022	Sell	1 070,00	0,53
01.12.2022	Sell	5 000,00	0,53
01.12.2022	Sell	5 000,00	0,53
01.12.2022	Sell	1 930,00	0,53
01.12.2022	Sell	3 070,00	0,53
01.12.2022	Sell	3 000,00	0,53
01.12.2022	Sell	1 000,00	0,53
01.12.2022	Sell	1 000,00	0,53
01.12.2022	Sell	900,00	0,53
01.12.2022	Sell	1 160,00	0,53

5 December 2022

NOTIFICATION

“Sopharma” AD notifies that it has received a notification from “Telso” AD that “Telso” AD has carried out the following transactions with warrants of “Sopharma” AD:

Date and time of the transaction	Operation	Number of warrants	Unit price (BGN)
02.12.2022	Sell	2 940,00	0,53
02.12.2022	Sell	5 000,00	0,53
02.12.2022	Sell	1 344,00	0,53
02.12.2022	Sell	3 656,00	0,53
02.12.2022	Sell	5 000,00	0,53

5 December 2022

Sales revenues for November 2022

Sofia, Bulgaria, December 5, 2022 – According to the requirements of art. 100t of LPOS, “Sopharma” AD (SFA: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that for November 2022 the Company recorded a decrease in sales of 6% compared to the same month of the previous year, incl. 8% decrease in domestic sales and 5% decrease in export sales.

For the eleven months since the beginning of the year the revenues from sales of products increase by 15%, incl. 10% increase of sales for the domestic market and 19% increase in export sales.

6 December 2022

NOTIFICATION

“Sopharma” AD notifies that it has received a notification from “Telso” AD that “Telso” AD has carried out the following transactions with warrants of “Sopharma” AD:

Date and time of the transaction	Operation	Number of warrants	Unit price (BGN)
05.12.2022	Sell	2 000,00	0,53

7 December 2022

NOTIFICATION

“Sopharma” AD notifies that it has received a notification from “Telso” AD that “Telso” AD has carried out the following transactions with shares of “Sopharma” AD:

Date and time of the transaction	Operation	Number of shares	Unit price (BGN)
06.12.2022	Buy	500,00	4,50

7 December 2022

NOTIFICATION

“Sopharma” AD notifies that it has received a notification from “Telso” AD that “Telso” AD has carried out the following transactions with warrants of “Sopharma” AD:

Date and time of the transaction	Operation	Number of warrants	Unit price (BGN)
06.12.2022	Sell	1 200,00	0,53
06.12.2022	Sell	1 700,00	0,53

12 December 2022

NOTIFICATION

“Sopharma” AD notifies that it has received a notification from “Telso” AD that “Telso” AD has carried out the following transactions with warrants of “Sopharma” AD:

Date and time of the transaction	Operation	Number of warrants	Unit price (BGN)
09.12.2022	Buy	6 499,00	0,50

14 December 2022

NOTIFICATION

“Sopharma” AD notifies that it has received a notification from “Telso” AD that “Telso” AD has carried out the following transactions with shares of “Sopharma” AD:

Date and time of the transaction	Operation	Number of shares	Unit price (BGN)
13.12.2022	Buy	100,00	4,46
13.12.2022	Buy	100,00	4,48

15 December 2022

NOTIFICATION

“Sopharma” AD notifies that it has received a notification from “Telso” AD that “Telso” AD has carried out the following transactions with shares of “Sopharma” AD:

Date and time of the transaction	Operation	Number of shares	Unit price (BGN)
14.12.2022	Buy	285,00	4,48
14.12.2022	Buy	300,00	4,48

19 December 2022

NOTIFICATION

“Sopharma” AD notifies that it has received a notification from “Telso” AD that “Telso” AD has carried out the following transactions with shares of “Sopharma” AD:

Date and time of the transaction	Operation	Number of shares	Unit price (BGN)
15.12.2022	Buy	400,00	4,46

20 December 2022

NOTIFICATION

“Sopharma” AD notifies that it has received a notification from “Telso” AD that “Telso” AD has carried out the following transactions with shares of “Sopharma” AD:

Date and time of the transaction	Operation	Number of shares	Unit price (BGN)
19.12.2022	Buy	168,00	4,46

21 December 2022

NOTIFICATION

“Sopharma” AD notifies that it has received a notification from “Telso” AD that “Telso” AD has carried out the following transactions with warrants of “Sopharma” AD:

Date and time of the transaction	Operation	Number of warrants	Unit price (BGN)
20.12.2022	Sell	1 000,00	0,47
20.12.2022	Sell	2 000,00	0,47

22 December 2022

NOTIFICATION

“Sopharma” AD notifies that it has received a notification from “Telso” AD that “Telso” AD has carried out the following transactions with shares of “Sopharma” AD:

Date and time of the transaction	Operation	Number of shares	Unit price (BGN)
21.12.2022	Buy	2 000,00	4,48
21.12.2022	Buy	1 813,00	4,48
21.12.2022	Buy	3 000,00	4,48
21.12.2022	Buy	2 000,00	4,46
21.12.2022	Buy	700,00	4,48
21.12.2022	Buy	100,00	4,48

22 December 2022

NOTIFICATION

“Sopharma” AD notifies that it has received a notification from “Telso” AD that “Telso” AD has carried out the following transactions with warrants of “Sopharma” AD:

Date and time of the transaction	Operation	Number of warrants	Unit price (BGN)
21.12.2022	Sell	1 300,00	0,46
21.12.2022	Sell	2 000,00	0,46
21.12.2022	Sell	4 700,00	0,46
21.12.2022	Sell	2 500,00	0,47

3 January 2023

NOTIFICATION

“Sopharma” AD notifies that it has received a notification from “Telso” AD that “Telso” AD has carried out the following transactions with warrants of “Sopharma” AD:

Date and time of the transaction	Operation	Number of warrants	Unit price (BGN)
23.12.2022	Sell	800,00	0,51

3 January 2023

NOTIFICATION

“Sopharma” AD (the “Company”) announces that it was notified by Mr Ivan Badinski, Member of the Board of Directors that he, executed the following transactions related to warrants in the Company:

Date of the transaction	Operation	Number of shares	Unit price (BGN)
12.12.2022	Buy	359	4,50
12.12.2022	Buy	121	4,50